90 related articles for article (PubMed ID: 25750287)
1. Flunarizine exhibits in vitro efficacy against lymphoma and multiple myeloma cells.
Schmeel LC; Schmeel FC; Kim Y; Blaum-Feder S; Endo T; Schmidt-Wolf IG
Anticancer Res; 2015 Mar; 35(3):1369-76. PubMed ID: 25750287
[TBL] [Abstract][Full Text] [Related]
2. In vitro efficacy of cinnarizine against lymphoma and multiple myeloma.
Schmeel LC; Schmeel FC; Kim Y; Blaum-Feder S; Endo T; Schmidt-Wolf IG
Anticancer Res; 2015 Feb; 35(2):835-41. PubMed ID: 25667464
[TBL] [Abstract][Full Text] [Related]
3. In Vitro Efficacy of Naftifine Against Lymphoma and Multiple Myeloma.
Schmeel LC; Schmeel FC; Blaum-Feder S; Schmidt-Wolf IG
Anticancer Res; 2015 Nov; 35(11):5921-6. PubMed ID: 26504016
[TBL] [Abstract][Full Text] [Related]
4.
Schmeel LC; Schmeel FC; Schmidt-Wolf IGH
Anticancer Res; 2017 Jul; 37(7):3513-3520. PubMed ID: 28668840
[TBL] [Abstract][Full Text] [Related]
5. Clofibrate Demonstrates Efficacy in In Vitro Treatment of Lymphoma and Multiple Myeloma.
Schmeel LC; Schmeel FC; Schmidt-Wolf IG
Anticancer Res; 2016 Jul; 36(7):3395-400. PubMed ID: 27354598
[TBL] [Abstract][Full Text] [Related]
6. Griseofulvin Efficiently Induces Apoptosis in
Schmeel LC; Schmeel FC; Kim Y; Blaum-Feder S; Schmidt-Wolf IGH
Anticancer Res; 2017 May; 37(5):2289-2295. PubMed ID: 28476794
[TBL] [Abstract][Full Text] [Related]
7. Targeting the Wnt/beta-catenin pathway with the antifungal agent ciclopirox olamine in a murine myeloma model.
Kim Y; Schmidt M; Endo T; Lu D; Carson D; Schmidt-Wolf IG
In Vivo; 2011; 25(6):887-93. PubMed ID: 22021681
[TBL] [Abstract][Full Text] [Related]
8. In vivo efficacy of griseofulvin against multiple myeloma.
Kim Y; Alpmann P; Blaum-Feder S; Krämer S; Endo T; Lu D; Carson D; Schmidt-Wolf IG
Leuk Res; 2011 Aug; 35(8):1070-3. PubMed ID: 21112630
[TBL] [Abstract][Full Text] [Related]
9. Lymphoma and myeloma cells are highly sensitive to growth arrest and apoptosis induced by artesunate.
Holien T; Olsen OE; Misund K; Hella H; Waage A; Rø TB; Sundan A
Eur J Haematol; 2013 Oct; 91(4):339-46. PubMed ID: 23869695
[TBL] [Abstract][Full Text] [Related]
10. Targeting the Wnt/beta-catenin pathway in multiple myeloma.
Schmeel LC; Schmeel FC; Kim Y; Endo T; Lu D; Schmidt-Wolf IG
Anticancer Res; 2013 Nov; 33(11):4719-26. PubMed ID: 24222106
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effects of (S)-HDAC42, a phenylbutyrate-derived histone deacetylase inhibitor, in multiple myeloma cells.
Bai LY; Omar HA; Chiu CF; Chi ZP; Hu JL; Weng JR
Cancer Chemother Pharmacol; 2011 Aug; 68(2):489-96. PubMed ID: 21072520
[TBL] [Abstract][Full Text] [Related]
12. The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma.
Munugalavadla V; Mariathasan S; Slaga D; Du C; Berry L; Del Rosario G; Yan Y; Boe M; Sun L; Friedman LS; Chesi M; Leif Bergsagel P; Ebens A
Oncogene; 2014 Jan; 33(3):316-25. PubMed ID: 23318440
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib disrupts tumour-dendritic cell interactions in myeloma and lymphoma: therapeutic implications.
Kukreja A; Hutchinson A; Mazumder A; Vesole D; Angitapalli R; Jagannath S; O'connor OA; Dhodapkar MV
Br J Haematol; 2007 Jan; 136(1):106-10. PubMed ID: 17222199
[TBL] [Abstract][Full Text] [Related]
14. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
[TBL] [Abstract][Full Text] [Related]
15. Promising preclinical activity of 2-methoxyestradiol in multiple myeloma.
Dingli D; Timm M; Russell SJ; Witzig TE; Rajkumar SV
Clin Cancer Res; 2002 Dec; 8(12):3948-54. PubMed ID: 12473611
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC
Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364
[TBL] [Abstract][Full Text] [Related]
17. Apoptosis inducing bivalent single-chain antibody fragments against CD47 showed antitumor potency for multiple myeloma.
Kikuchi Y; Uno S; Kinoshita Y; Yoshimura Y; Iida S; Wakahara Y; Tsuchiya M; Yamada-Okabe H; Fukushima N
Leuk Res; 2005 Apr; 29(4):445-50. PubMed ID: 15725479
[TBL] [Abstract][Full Text] [Related]
18. Enhanced anticancer efficacy of snake venom combined with silica nanoparticles in a murine model of human multiple myeloma: molecular targets for cell cycle arrest and apoptosis induction.
Al-Sadoon MK; Rabah DM; Badr G
Cell Immunol; 2013; 284(1-2):129-38. PubMed ID: 23973876
[TBL] [Abstract][Full Text] [Related]
19. In vivo efficacy of the diuretic agent ethacrynic acid against multiple myeloma.
Kim Y; Gast SM; Endo T; Lu D; Carson D; Schmidt-Wolf IG
Leuk Res; 2012 May; 36(5):598-600. PubMed ID: 22386728
[TBL] [Abstract][Full Text] [Related]
20. The Fc portion of UV3, an anti-CD54 monoclonal antibody, is critical for its antitumor activity in SCID mice with human multiple myeloma or lymphoma cell lines.
Coleman EJ; Brooks KJ; Smallshaw JE; Vitetta ES
J Immunother; 2006; 29(5):489-98. PubMed ID: 16971805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
